ResourceDrug Discovery & Development
CNS drug development
9 Jan 2023In this white paper, QPS describes how it provides essential preclinical and clinical research services to help pharmaceutical and biotechnology companies around the globe accelerate the discovery and development of drugs to prevent, treat, and cure brain diseases, with a special focus on age-related neurodegenerative disorders such as Alzheimer’s and Parkinson’s Disease.
Related Products
Request Quote for All Products
QPS Neuropharmacology Animal Models for Central Nervous System Diseases
QPSThe QPS preclinical Neuropharmacology group covers various validated transgenic and non-transgenic in vivo and in vitro models for neurodegeneration such as Alzheimer’s Disease, Parkinson’s Disease, for rare diseases including Huntington’s Disease and ALS, for lipid storage disease and dyslipidemia, and for diseases like psychosis, anxiety, schizophrenia, or autism.